<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02747914</url>
  </required_header>
  <id_info>
    <org_study_id>LK-5</org_study_id>
    <nct_id>NCT02747914</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation for Lower Limb Spasticity in Multiple Sclerosis Patients</brief_title>
  <official_title>Repetitive Transcranial Magnetic Stimulation Boosted Exercise Therapy for Lower Limb Spasticity in Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Belgrade</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Belgrade</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leg spasticity is common problem encountered with a large proportion of patients suffering&#xD;
      with multiple sclerosis (MS) with an increasing severity as the disease progresses. It mostly&#xD;
      affects the antigravity muscles that significantly complicates transfer, increases fatigue&#xD;
      and makes walking more difficult. Hence, leg spasticity often interferes with patients'&#xD;
      mobility and significantly influences their quality of life. A great number of&#xD;
      multidisciplinary rehabilitation studies has shown a significant effect of numerous specific&#xD;
      functional changes in patients with secondary (SP) and primary progressive (PP) MS but there&#xD;
      are no reviews related to spasticity. The positive therapeutic effect of modulating&#xD;
      Transcranial Magnetic Stimulation ( TMS) methods on spasticity is shown in only two studies,&#xD;
      in patients with relapse remitting clinical form in the remission phase of the disease. The&#xD;
      effect of TMS on clinical measures of lower limb spasticity, functional inability and the&#xD;
      quality of life in patients with SPMS and PPMS will be examined in this study. The objective&#xD;
      to this study are to to explore whether rTMS boosted exercise therapy (ET) treatment can&#xD;
      bring more improvement in lower limb spasticity than ET treatment alone in these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle tone measured by Modified Ashworth Scale (MAS)</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>impact of leg spasticity on daily activities measured by Multiple Sclerosis Spasticity Scale 88 (MSSS-88)</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living measured by Barthel Index</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking mobility measured by Timed 25 Foot Walk test</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by Multiple Sclerosis Quality of Life 54 (MSQoL54).</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Transcranial magnetic stimulation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of patients treated with rTMS low than 5Hz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional exercise treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of patients treated with conventional exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial magnetic stimulation</intervention_name>
    <description>TMS 1Hz under the motor zone of cortex.</description>
    <arm_group_label>Transcranial magnetic stimulation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional exercise</intervention_name>
    <description>Exercise will be administrated in a conventional way.</description>
    <arm_group_label>Conventional exercise treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed clinical form of SPMS and PPMS (established on the basis of the revised&#xD;
             McDonald criteria)&#xD;
&#xD;
          -  EDDS score 2-6.5&#xD;
&#xD;
          -  lower limb spasticity caused by MS&#xD;
&#xD;
          -  18 years ≥age of the patient ≤ 65. years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinical worsening of the disease over the past 30 days,&#xD;
&#xD;
          -  the presence of pregnancy, dementia, alcoholism, history of loss of consciousness,&#xD;
             epilepsy, metal objects in the head, pacemakers and other electronic devices in the&#xD;
             body at a distance of 20cm from the top of the patients head, serious associate&#xD;
             diseases (malignancy, heart disease).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ljubica Konstantinovic</last_name>
    <phone>063323996</phone>
    <email>ljubica.konstantinovic@med.bg.ac.rs</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinic for rehabilitation dr Miroslav Zotovic Faculty of Medicine University of Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ljubica M Konstantinovic, PhDMD</last_name>
      <phone>+381112061513</phone>
      <email>ljubica.konstantinovic@med.bg.ac.rs</email>
    </contact>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Belgrade</investigator_affiliation>
    <investigator_full_name>Konstantinovic Ljubica</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

